Last Updated: November 16, 2026

Investigational Drug Information for Camptothecin

« Back to Dashboard


What is the drug development status for Camptothecin?

Camptothecin is an investigational drug.

There have been 155 clinical trials for Camptothecin. The most recent clinical trial was a Phase 3 trial, which was initiated on May 6th 2025.

The most common disease conditions in clinical trials are Neoplasms, Adenocarcinoma, and Lung Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Astex Pharmaceuticals, and Astex Pharmaceuticals, Inc.

There are zero US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for Camptothecin
TitleSponsorPhase
CEB-01 in Paediatrics With Locally Resectable Abdominal TumoursCEBIOTEXPHASE2
64Cu/68Ga Labelled EB-ss-CPT PET/CT Scan in Colorectal CancerPeking Union Medical College HospitalEarly Phase 1
A Trial of NIS793 With FOLFIRINOX in Pancreatic CancerNovartisPhase 2

See all Camptothecin clinical trials

Clinical Trial Summary for Camptothecin

Top disease conditions for Camptothecin
Top clinical trial sponsors for Camptothecin

See all Camptothecin clinical trials

US Patents for Camptothecin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Camptothecin ⤷  Start Trial Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor The Regents of the University of California (Oakland, CA) ⤷  Start Trial
Camptothecin ⤷  Start Trial Methods and compositions for treating infection UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS) ⤷  Start Trial
Camptothecin ⤷  Start Trial Solid forms of an epidermal growth factor receptor kinase inhibitor Celgene CAR LLC (Pembroke, BM) ⤷  Start Trial
Camptothecin ⤷  Start Trial Salts of an epidermal growth factor receptor kinase inhibitor Celgene CAR LLC (Pembroke, BM) ⤷  Start Trial
Camptothecin ⤷  Start Trial Amide compounds for treatment of complement mediated disorders Achillion Pharmaceuticals Inc ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Camptothecin

Drugname Country Document Number Estimated Expiration Related US Patent
Camptothecin European Patent Office EP2748329 2031-11-07 ⤷  Start Trial
Camptothecin European Patent Office EP3581660 2031-11-07 ⤷  Start Trial
Camptothecin Spain ES2733042 2031-11-07 ⤷  Start Trial
Camptothecin World Intellectual Property Organization (WIPO) WO2013070807 2031-11-07 ⤷  Start Trial
Camptothecin World Intellectual Property Organization (WIPO) WO2014052836 2032-09-27 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent
Last updated: September 1, 2026

Camptothecin is not an approved drug and has no standalone commercial market. Its clinical value is concentrated in derivatives that inhibit topoisomerase I, principally irinotecan, topotecan and liposomal irinotecan. Native camptothecin development was constrained by poor aqueous solubility, unstable lactone chemistry and dose-limiting toxicity. Future value is more likely to come from targeted delivery systems and next-generation camptothecin analogues than from the unmodified molecule.

Camptothecin Development Update and Market Projection

What is the current development status of camptothecin?

Native camptothecin is a natural-product topoisomerase I inhibitor that is not approved by the U.S. Food and Drug Administration. It was isolated from Camptotheca acuminata and entered early oncology development, but systemic use was limited by insolubility, toxicity and formulation problems.

The commercial development path shifted to analogues with improved pharmacology:

Compound Relationship to camptothecin Current status Principal commercial sponsor or manufacturer
Camptothecin Parent compound Not FDA approved; no established marketed product No single current global sponsor
Irinotecan Semisynthetic camptothecin derivative FDA approved Generic manufacturers; branded products include Camptosar
Topotecan Semisynthetic camptothecin derivative FDA approved Generic manufacturers; branded product historically Hycamtin
Liposomal irinotecan Nanoparticle formulation of irinotecan FDA approved as Onivyde Servier
Exatecan Water-soluble camptothecin analogue Development discontinued in several programs Historical development by Daiichi Sankyo and others
Belotecan Camptothecin analogue Marketed in South Korea; limited international penetration Chong Kun Dang
Trastuzumab deruxtecan payload system Uses a camptothecin-derived topoisomerase I inhibitor payload Approved antibody-drug conjugate Daiichi Sankyo and AstraZeneca

The FDA-approved camptothecin-derived products validate the mechanism, but they do not create an approval or exclusivity position for native camptothecin.

What drugs are derived from camptothecin?

Irinotecan

Irinotecan is converted in vivo to SN-38, the active topoisomerase I inhibitor. The drug is used in colorectal cancer and other oncology regimens. FDA approval dates to 1996, and the original small-molecule exclusivity and patent estate have expired. Generic irinotecan is widely available.

Irinotecan remains the largest commercial platform linked to camptothecin because it is used across multiple colorectal cancer treatment lines and is incorporated into combination regimens such as FOLFIRI.

Topotecan

Topotecan is approved for ovarian cancer, small-cell lung cancer and cervical cancer indications. The original branded product has faced generic competition for years. Commercial growth is limited by mature-market competition and the availability of newer therapies.

Liposomal irinotecan

Onivyde is a liposomal formulation designed to modify irinotecan exposure and delivery. The FDA initially approved it for metastatic pancreatic adenocarcinoma after gemcitabine-based therapy. The product later received an FDA indication for first-line treatment of metastatic pancreatic adenocarcinoma in combination with oxaliplatin, fluorouracil and leucovorin in 2024. The approval expanded the addressable market while adding competition from other pancreatic cancer regimens.[1]

The product is protected primarily through formulation, delivery and method-of-use rights rather than through the expired irinotecan molecule.

What FDA regulatory status applies to camptothecin products?

Native camptothecin has no FDA approval, no approved labeling and no Orange Book-listed reference product. Irinotecan, topotecan and Onivyde are regulated as separate drug products.

Product FDA status Orange Book position Regulatory exposure
Native camptothecin Not approved No reference listing Development would require a new drug application or applicable investigational pathway
Irinotecan injection Approved Listed drug and generic reference framework High generic competition
Topotecan injection and capsules Approved Listed drug and generic reference framework High generic competition
Onivyde Approved Listed branded drug with product-specific protections Paragraph IV and formulation-patent risk depends on listed patents and timing

The Orange Book does not create protection for a pharmacologically related compound merely because the compound shares a camptothecin mechanism. Each active ingredient, formulation and indication requires its own regulatory and intellectual-property analysis.[2]

What patents protect camptothecin and its derivatives?

The core camptothecin molecule is an old natural product. Any original composition-of-matter protection is expired or otherwise incapable of supporting new-product exclusivity in the United States and most major pharmaceutical markets.

Potentially relevant protection can still arise from:

  • New camptothecin analogues
  • Salt, polymorph and crystalline forms
  • Liposomal, polymeric or nanoparticle formulations
  • Prodrugs that stabilize the lactone ring
  • Antibody-drug conjugates using camptothecin-derived payloads
  • Combination regimens
  • Biomarker-selected treatment methods
  • Manufacturing processes that improve purity or yield

The strongest surviving rights are usually formulation and method-of-use patents. They do not prevent all use of native camptothecin or all use of irinotecan. Their scope depends on claim construction, written-description support, enablement and the specific formulation or patient population.

How strong is the patent estate for native camptothecin?

The patent estate for native camptothecin is weak for direct commercialization. The molecule is old, publicly disclosed and clinically established. A new sponsor would need to differentiate through delivery, selectivity, safety or a disease-specific treatment method.

The estate is stronger for newer platforms that use camptothecin-derived payloads. Examples include antibody-drug conjugates, tumor-activated prodrugs and long-acting delivery systems. Those products can obtain composition, linker, payload, conjugation and method-of-use claims that are independent of the expired parent compound.

What formulation patents are relevant?

Formulation patents can address:

  • Maintenance of the active lactone form
  • Reduced systemic exposure to the carboxylate form
  • Improved aqueous dispersibility
  • Controlled release
  • Tumor-targeted delivery
  • Reduced gastrointestinal and hematologic toxicity
  • Compatibility with infusion or injectable dosage forms

Onivyde illustrates the commercial value of formulation protection. Its competitive position does not depend on a new irinotecan molecule. It depends on the liposomal delivery system, approved clinical use and associated regulatory exclusivity.

When does camptothecin lose exclusivity?

Native camptothecin has no meaningful remaining U.S. market exclusivity because it was never approved as a branded product. The original composition is too old to support a new regulatory monopoly.

Asset type Expected exclusivity position
Native camptothecin No current FDA market exclusivity
Generic irinotecan Molecule and original product protections expired
Generic topotecan Molecule and original product protections expired
Onivyde Product-specific patents and regulatory protections may remain relevant; expiration depends on the individual Orange Book listing
New camptothecin analogue Potentially eligible for five years of new chemical entity exclusivity if it qualifies
New formulation Potentially eligible for three years of clinical-investigation exclusivity if statutory requirements are met
Orphan indication Potentially eligible for seven years of orphan-drug exclusivity in the United States

Exact expiration dates must be determined from the current FDA Orange Book, patent-term-adjustment records and litigation outcomes. A molecule-level date cannot be applied to all camptothecin-derived products.

Which companies are challenging camptothecin-derived products?

Generic manufacturers have challenged or entered against irinotecan and topotecan after expiry of their principal protections. Competition includes manufacturers of injectable oncology products in the United States, Europe, India and China.

Onivyde has a different risk profile. A generic applicant would need to address the drug’s liposomal formulation, bioequivalence requirements and listed patents. A conventional irinotecan injection is not automatically substitutable for a liposomal irinotecan product.

The main commercial challengers are therefore:

  1. Generic irinotecan manufacturers competing on price.
  2. Generic topotecan manufacturers competing in mature indications.
  3. Developers of alternative liposomal or nanoparticle irinotecan products.
  4. New pancreatic cancer regimens that compete clinically rather than through pharmaceutical equivalence.
  5. Developers of antibody-drug conjugates using topoisomerase I inhibitor payloads.

What Paragraph IV challenges and litigation affect camptothecin products?

Paragraph IV litigation is most relevant to branded formulation products such as Onivyde, not to native camptothecin. A generic applicant may certify that an Orange Book-listed patent is invalid, unenforceable or not infringed. The sponsor can then bring a patent-infringement action, potentially triggering a 30-month stay of FDA approval under the Hatch-Waxman framework.[3]

The commercial consequences depend on:

  • The number and scope of listed patents
  • Whether the generic uses the same liposomal structure
  • Whether the proposed label overlaps protected indications
  • Whether the parties settle
  • Whether the generic receives tentative approval
  • The date of any first commercial launch

No biosimilar pathway applies to camptothecin, irinotecan or topotecan because these are small-molecule drugs. A biosimilar risk analysis is relevant only to biologics, not to camptothecin-derived products.

What licensing deals affect camptothecin technology?

The most commercially important licensing and collaboration activity has involved camptothecin-derived payloads rather than native camptothecin.

Daiichi Sankyo and AstraZeneca developed and commercialized trastuzumab deruxtecan, an antibody-drug conjugate that uses a camptothecin-derived topoisomerase I inhibitor payload. The product demonstrates the value of coupling the mechanism to antibody targeting rather than administering camptothecin systemically.[4]

Other development programs have used camptothecin analogues in:

  • Antibody-drug conjugates
  • Polymer-drug conjugates
  • Nanoparticles
  • Tumor-activated prodrugs
  • Topoisomerase I inhibitor combinations

These transactions generally protect platform technology, linker chemistry, payload composition and therapeutic use. They do not imply that the parent camptothecin molecule has remaining exclusivity.

What is the competitive landscape for camptothecin-derived therapies?

Camptothecin-derived products compete in three distinct markets.

Conventional topoisomerase I inhibitors

Irinotecan and topotecan compete with generic pricing, established clinical protocols and physician familiarity. Their growth is constrained by maturity but supported by continuing oncology demand.

Long-acting and targeted formulations

Onivyde and investigational delivery systems seek to improve exposure, tolerability or tumor concentration. These products can command higher prices but face formulation-development, manufacturing and clinical-validation barriers.

Antibody-drug conjugates

Camptothecin-derived payloads are increasingly used in ADCs. The competitive advantage comes from antigen targeting and payload release, not from the parent compound alone. Key competitors include ADCs using deruxtecan, sacituzumab govitecan and other topoisomerase I inhibitor payloads.

What manufacturing and intellectual-property barriers exist?

Native camptothecin can be obtained through plant extraction or chemical synthesis, but commercial development requires control of impurity profiles, stereochemistry, lactone stability and reproducible drug-product performance.

The main manufacturing barriers are:

  • Low aqueous solubility
  • Lactone-ring hydrolysis
  • Batch-to-batch variability in natural-source material
  • Difficult sterile injectable formulation
  • Control of particle size and encapsulation efficiency
  • Scale-up of liposomal or conjugated delivery systems
  • Analytical separation of active and inactive forms
  • Payload-linker consistency for ADCs

These barriers can support process patents and trade secrets, but they do not restore exclusivity to the old molecule.

What is the market projection for camptothecin?

The standalone market for native camptothecin is effectively zero because there is no approved branded product with material commercial sales.

A practical market projection should therefore separate native camptothecin from the broader camptothecin-derived market:

Market segment Near-term outlook Main growth driver Main constraint
Native camptothecin Negligible commercial market Research use and experimental delivery systems No approval, toxicity and poor solubility
Generic irinotecan Stable to modest growth in volume Global cancer incidence and continued colorectal cancer use Price erosion
Generic topotecan Flat to modest growth Ovarian, cervical and small-cell lung cancer demand Mature generic competition
Onivyde Growth opportunity Expanded pancreatic cancer indication Formulation patents, reimbursement and competing regimens
Camptothecin-payload ADCs Highest growth potential Targeted oncology and premium pricing Clinical failure, manufacturing complexity and crowded ADC field

The strongest market projection is for the broader topoisomerase I inhibitor and ADC categories, not for camptothecin itself. Revenue growth will depend on whether new delivery technologies demonstrate a clinically meaningful therapeutic index and secure differentiated regulatory indications.

A reasonable strategic forecast is:

  • Native camptothecin: no material branded revenue without a major reformulation or targeted-delivery approval.
  • Generic irinotecan and topotecan: volume growth offset by continuing price compression.
  • Liposomal irinotecan: moderate growth potential from pancreatic cancer expansion, subject to formulary adoption and competitive data.
  • Camptothecin-derived ADCs: highest potential revenue contribution, but also the highest clinical, manufacturing and regulatory risk.

Public market reports often combine camptothecin, irinotecan, topotecan, liposomal products and ADC payload technologies into a single market estimate. Those figures are not directly comparable and should not be used as a standalone valuation for native camptothecin.

What generic launch scenarios exist for camptothecin-derived products?

Native camptothecin

A generic launch is not applicable because there is no FDA-approved reference product. A sponsor would need to pursue an original development program.

Irinotecan and topotecan

Generic entry is established. Price competition and hospital purchasing pressure are the principal risks to branded revenue.

Onivyde

A successful generic or follow-on launch would likely depend on demonstrating pharmaceutical equivalence to a complex liposomal product and overcoming formulation-patent claims. The launch could be:

  • At-risk, after a Paragraph IV challenge and before final patent resolution
  • Delayed under a settlement agreement
  • Limited to non-infringing indications through a skinny label
  • Deferred until relevant patents expire or are invalidated

What geographic markets offer the greatest opportunity?

The United States remains the most valuable market for differentiated camptothecin-derived products because of oncology pricing and reimbursement. Europe offers broad access but greater price controls and health-technology-assessment scrutiny. China has substantial oncology demand and growing domestic manufacturing capacity, but local competition and procurement policies can reduce prices.

Japan and South Korea remain relevant for topoisomerase I inhibitors and regional camptothecin analogues. India and China are important manufacturing bases for active pharmaceutical ingredients and generic injectables.

Geographic patent coverage is likely to be strongest for new formulations and ADC platforms in the United States, Europe, Japan and China. Native camptothecin itself has no meaningful geographic exclusivity advantage.

Key Takeaways

  • Native camptothecin is not FDA approved and has no standalone commercial market.
  • Its clinical and commercial importance comes from derivatives such as irinotecan, topotecan and liposomal irinotecan.
  • The parent compound’s old composition cannot support new U.S. exclusivity.
  • Formulation, delivery, method-of-use and ADC-payload patents provide the main remaining IP opportunities.
  • Generic competition is established for irinotecan and topotecan.
  • Onivyde has the clearest branded formulation opportunity, supported by liposomal delivery and pancreatic cancer use.
  • Camptothecin-derived ADCs have the highest growth potential but also the greatest development and manufacturing risk.
  • Market estimates that aggregate native camptothecin with all derivatives materially overstate the opportunity for the parent molecule.

FAQs

Is camptothecin available as a prescription medicine?

No. Native camptothecin is not an FDA-approved prescription medicine. Approved products use related derivatives or formulations.

Is irinotecan the same as camptothecin?

No. Irinotecan is a semisynthetic derivative that is converted to SN-38, the active topoisomerase I inhibitor. It is chemically and regulatory distinct from camptothecin.

Can a company patent a new camptothecin formulation?

Yes. A new formulation may qualify for patent protection if it is novel, non-obvious and adequately supported. The patent would protect the formulation claims, not the old camptothecin molecule generally.

Are camptothecin drugs exposed to biosimilar competition?

No. Camptothecin, irinotecan and topotecan are small molecules. Competition proceeds through generic-drug pathways rather than biosimilar regulation.

Which camptothecin-derived product has the strongest commercial outlook?

Camptothecin-payload ADCs have the highest growth potential. Among conventional products, liposomal irinotecan has the clearest opportunity for differentiated branded revenue, while irinotecan and topotecan remain mature generic markets.

References

  1. U.S. Food and Drug Administration. (2024). FDA approves liposomal irinotecan combination for first-line treatment of metastatic pancreatic adenocarcinoma. FDA.

  2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

  3. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).

  4. U.S. Food and Drug Administration. (2019). FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic breast cancer. FDA.

  5. National Cancer Institute. (2023). Camptothecin. National Cancer Institute.

  6. U.S. Food and Drug Administration. (2023). Camptosar prescribing information: Irinotecan hydrochloride injection. FDA.

  7. U.S. Food and Drug Administration. (2023). Hycamtin prescribing information: Topotecan hydrochloride. FDA.

  8. U.S. Food and Drug Administration. (2024). Onivyde prescribing information: Irinotecan liposome injection. FDA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.